Pasithea Therapeutics Corp. Logo

Pasithea Therapeutics Corp.

Developing innovative therapeutics for CNS disorders (ALS, MS) and RASopathies.

KTTA | US

Overview

Corporate Details

ISIN(s):
US70261F1030
LEI:
Country:
United States of America
Address:
1111 LINCOLN ROAD, SUITE 500, 33139 MIAMI BEACH
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pasithea Therapeutics Corp. is a clinical-stage biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders and RASopathies. The company is dedicated to creating new therapeutics for complex neurological and psychiatric conditions with significant unmet medical needs. Its primary research pipeline targets treatments for Neurofibromatosis type 1 (NF1), Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and schizophrenia.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-04 13:04
Regulatory News Service
8-K - Pasithea Therapeutics Corp. (0001841330) (Filer)
English 145.9 KB

Automate Your Workflow. Get a real-time feed of all Pasithea Therapeutics Corp. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pasithea Therapeutics Corp.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pasithea Therapeutics Corp. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Coherus Oncology, Inc. Logo
Commercial-stage biopharma developing immuno-oncology therapies for hard-to-treat cancers.
United States of America CHRS
COLLEGIUM PHARMACEUTICAL, INC Logo
Develops and commercializes abuse-deterrent medications for responsible chronic pain management.
United States of America COLL
CollPlant Biotechnologies Ltd Logo
Develops rhCollagen for 3D bioprinting of tissues for regenerative & aesthetic medicine.
United States of America CLGN
Compass Therapeutics, Inc. Logo
A clinical-stage oncology firm developing antibody therapies that engage the immune system.
United States of America CMPX
Compugen Ltd. Logo
Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.
Israel CGEN
COMPUGEN LTD Logo
AI-driven discovery of novel cancer immunotherapies for treatment-resistant patients.
United States of America CGEN
Connect Biopharma Holdings Ltd Logo
Develops immune modulators for T cell-driven inflammatory diseases like asthma and COPD.
United States of America CNTB
Context Therapeutics Inc. Logo
Clinical-stage biopharma developing T cell engaging bispecific antibodies for solid tumors.
United States of America CNTX
Contineum Therapeutics, Inc. Logo
Develops oral small molecule therapies for neurological, inflammatory, and fibrotic diseases.
United States of America CTNM
CORCEPT THERAPEUTICS INC Logo
Develops and commercializes cortisol-modulating drugs for severe disorders like Cushing's syndrome.
United States of America CORT

Talk to a Data Expert

Have a question? We'll get back to you promptly.